TITLE

WHEN SHOULD ANTACIDS BE INGESTED AFTER MEALS?

AUTHOR(S)
Anggiansah, R.; Chandra, A.; Anggiansah, A.; Owen, W.J.
PUB. DATE
April 2003
SOURCE
Gut;Apr2003 Supplement 1, Vol. 52, pA43
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Introduction: Post-prandial reflux (PPR) is a significant component of gastro-oesophagea[reflux GOR) in health anddisease. PPR is generally analysed within 2 hours after meals. Various studies have attempted to modify PPR to determine the effectiveness of intervention. However, there is little documentation regarding when maximal PPR occurs. Aim: This study examined the PPR profile of pathological GOR patients. Patients and Methods: A sample of 55 patients (32 males, mean age 50.3 years) was chosen randomly from those with pHdocumented GOR disease who had attended the unit in 2002. During 24 hr pH monitoring (Synectics), patients were advised to go about their normal activities and had their usual meals but avoiding food or drink with pH <5. GOR was defined as pH <4. The two-hour PPR periods were divided into 30 min quarters. Kruskai-Wallis and Mann-Whitney statistical tests were used. Results: There were no significant differences in PPR comparing meals (p=0.92). However, there were significant differences in PPR ~quarters for each meal (p≤0.03). The greatest acid exposure after breakfast was in the 2nd quarter, which was significantly higher than the 1st (p=0.003) and the 4th quarters (p=0.002). After lunch and dinner, the highest GOR occurred in the 3rd quarter, which in both was significantly higher than the 1st quarter (p≤0.03) only. Conclusion: PPR is a ma or source of GOR and in this group of patients up to 74.4% of the post-prandial period demonstrated acid exposure. Maximal PPR occurs in the 2nd or 3rd quarter of the postprandial period. For maximal effect patients with pathological GOR should ingest antacids half an hour after meals.
ACCESSION #
9747557

 

Related Articles

  • Short-term Treatment of Gastroesophageal Reflux Disease. van Pinxteren, Bart; Numans, Mattijs E.; Lau, Joseph; de Wit, Niek J; Hungin, A. Pali S.; Bonis, Peter A.L. // JGIM: Journal of General Internal Medicine;Sep2003, Vol. 18 Issue 9, p755 

    OBJECTIVE: To investigate the efficacy of acid suppressant drugs in the empirical treatment of gastroesophageal reflux disease (GERD) and in the treatment of endoscopy-negative reflux disease (ENRD). DESIGN: medline, embase, and the Cochrane Controlled Trials Register were searched....

  • Selection of Drugs to Treat Gastro-Oesophageal Reflux Disease. Flockhart, David A.; Desta, Zeruesenay; Mahal, Subena K. // Clinical Pharmacokinetics;2000, Vol. 39 Issue 4, p295 

    Gastro-oesophageal reflux disease is probably the most common acid-peptic disease in Western countries, and the successful treatment of mild to moderate disease with pharmacotherapy has become commonplace. A large number of effective drugs are now available, and so the decision-making process...

  • Sucralfate: Nonulcer Uses. Brooks Jr., W. Scott // American Journal of Gastroenterology;Mar1985, Vol. 80 Issue 3, p206 

    Recent studies have shown sucralfate to have cytoprotective features in addition to its known antipepsin and antacid effects. This drug has been shown in limited studies to prevent gastric salicylate injury with pretreatment. A role for sucralfate in the nonulcer population, patients with...

  • alganic acid.  // Royal Society of Medicine: Medicines;2002, p44 

    The article presents information on alganic acid which is extracted from seaweed, usually in the form of alginate. It has a viscous, sticky consistency and is used as a demulcent in certain antacid preparations to protect against reflux esophagitis. Alganic acid is also incorporated in some...

  • magnesium trisilicate.  // Royal Society of Medicine: Medicines;2002, p346 

    This article presents information on magnesium trisilicate, an antacid with long duration of action. It is a constituent of many proprietary preparations that are used to relieve hyperacidity and dyspepsia and for the symptomatic relief of heartburn or a peptic ulcer. Administration is oral. It...

  • Ways to Avoid "Heartburn Season.".  // USA Today Magazine;Dec2007, Vol. 136 Issue 2751, p2 

    The article provides information on heartburn and offers tips on how to prevent and treat the condition. According to the article, heartburn most often is caused by the reflux or backwash of acid from the stomach up into the esophagus, which is the long tube that carries food from the throat to...

  • A prospective longitudinal cohort study: evolution of GERD symptoms during the course of pregnancy. Malfertheiner, Sara Fill; Malfertheiner, Maximilian V.; Kropf, Siegfried; Costa, Serban-Dan; Malfertheiner, Peter // BMC Gastroenterology;2012, Vol. 12 Issue 1, p131 

    Background: Symptoms of gastro-esophageal reflux disease (GERD) in pregnancy are reported with a prevalence of 30-80%. The aim of this study was to assess the prevalence and severity of GERD symptoms during the course of pregnancy. Furthermore current practice in medical care for GERD during...

  • Updated Guidelines for the Diagnosis and Treatment of Gastroesophageal Reflux Disease. DeVault, Kenneth R.; Castell, Donald O. // American Journal of Gastroenterology;Jun1999, Vol. 94 Issue 6, p1434 

    Provides information on updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease (GERD), as of June 1999. Changes made to endoscopy in GERD; Effect of antacids and antirefluxants on GERD; Type of maintenance therapy appropriate for GERD.

  • alginates. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p30 

    An encyclopedia entry for "alginates" is presented. It refers to substances used as an ingredient in certain kinds of antacid drugs. It is noted that these substances stay on top of the stomach contents which prohibits the occurrence of acid reflux. It is also asserted that alginates protect the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics